Efficacy of low dose azithromycin in recurrent furunculosis

Authors

  • Dr. Zaib
  • Farwa Naqvi
  • Sara Inayat
  • Amna Mubeen
  • Fida Muhammad
  • Ahmed Amin Khan Faraz
  • Muhammad Mustafa Qamar

DOI:

https://doi.org/10.66344/jpad.30.4.2020.1635

Keywords:

Azithromycin, recurrent furunculosis

Abstract

Aim To access the efficacy of low dose azithromycin in recurrent furunculosis. Methods This study was conducted at the Outpatient Department of Dermatology, DHQ teaching Hospital, Sargodha Medical College Sargodha, from January 2019 to December 2019. Total 180 patients aged between 20 and 60 years of recurrent furunculosis were divided into two groups. Both groups washed body with chlorhexidine soap daily, applied 2% mupirocin on lesion and in nostrils twice daily and took oral 400mg -600mg tablet linezolid twice daily for 10-14 days. Group A was offered no added treatment but Group B was prescribed azithromycin 500mg once weekly for next 3 months. The drug is considered efficacious if the patient had no episode of furuncles during the 3â€month followâ€up period of the treatment. Results  In group A, 32 patients (36%) reported back with recurrent furunculosis in contrast with only 9 patients (10%) of group A reported with recurrent furunculosis. Conclusion It is concluded that low dose azithromycin is far better than patient receiving no treatment for recurrent furunculosis. So, we should consider low dose azithromycin as a promising alternative for treatment of recurrent furunculosis. 

References

Jain AKC. Carbuncle is an Uncle of Furuncle‖–A case report. EAS J Med Surg. 2019;1(6):175–6.

Ibler KS, Kromann CB. Recurrent furunculosis–challenges and management: a review. Clin Cosmet Investig Dermatol. 2014;7:59.

Nowicka D, Grywalska E. Staphylococcus aureus and Host Immunity in Recurrent Furunculosis. Dermatology. 2019; 235(4): 295–305.

Demos M, McLeod MP, Nouri K. Recurrent furunculosis: a review of the literature. Br J Dermatol. 2012;167(4):725–32.

Davido B, Dinh A, Salomon J, Roux AL, Gosset-Woimant M, Pierre I, et al. Recurrent furunculosis: Efficacy of the CMC regimen—skin disinfection (chlorhexidine), local nasal antibiotic (mupirocin), and systemic antibiotic (clindamycin). Scand J Infect Dis. 2013; 45(11):837–41.

Smith K, Perez A, Ramage G, Gemmell CG, Lang S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents. 2009; 33(4):374–8.

Aminzadeh A, Demircay Z, Ocak K, Soyletir G. Prevention of chronic furunculosis with lowâ€dose azithromycin. J Dermatolog Treat. 2007;18(2):105–8.

Renteria AE, Maniakas A, Mfuna LE, Asmar M, Gonzalez E, Desrosiers M. Lowâ€dose and longâ€term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients. In: International Forum of Allergy & Rhinology. Wiley Online Library; 2020.

Shallcross LJ, Hayward AC, Johnson AM, Petersen I. Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care. Br J Gen Pract. 2015;65(639):e668–76.

Roudebush P, Schoenherr WD. Skin and hair disorders. Small Anim Clin Nutr. 2010;637–43.

Hamaliaka A, Novikova I. Nitric oxide production disorders in leukocytes of patients with recurrent furunculosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.2010;154(2):163–7.

Mashhood AA, Shaikh ZI, Qureshi SM, Malik SM. Efficacy of rifampicin in eradication of carrier state of Staphylococcus aureus in anterior nares with recurrent furunculosis. J Coll Physicians Surg Pak. 2006;16(6):396–9.

Downloads

Published

2021-01-04

How to Cite

1.
Zaib D, Naqvi F, Inayat S, Mubeen A, Muhammad F, Faraz AAK, Qamar MM. Efficacy of low dose azithromycin in recurrent furunculosis. J Pak Assoc Dermatol [Internet]. 2021Jan.4 [cited 2026May3];30(4):662-7. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1635

Issue

Vol. 30 No. 4 (2020): October - December

Section

Original Articles

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

Most read articles by the same author(s)

1 2 > >>